<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90565">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01711853</url>
  </required_header>
  <id_info>
    <org_study_id>1160.166</org_study_id>
    <secondary_id>2011-003081-32</secondary_id>
    <nct_id>NCT01711853</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.</brief_title>
  <official_title>An Exploratory Study to Investigate the Pharmacokinetics and Effects of DABIgatran Etexilate in Patients With Stable Severe RENAL Disease: DabiRenal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Netherlands: Central Committee Research Involving Human Subjects</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study to be conducted is a prospective,  open label trial. It is designed to evaluate
      the pharmacokinetic/pharmacodynamic and coagulation parameters and safety of dabigatran
      etexilate in patients with chronic kidney disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 11 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCt,ss  (area under the concentration curve of the analyte in plasma at steady state over a uniform dosing interval)</measure>
    <time_frame>up to 11 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Dabigatran Etexilate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient to receive a capsule containing 75 mg of dabigatran etexilate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Etexilate</intervention_name>
    <description>Dabigatran Etexilate 75mg twice daily</description>
    <arm_group_label>Dabigatran Etexilate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Male and female patients aged 18 years and older

          2. Impaired renal function defined as a stable Cockroft-Gault and/or actual creatinine
             clearance between 15-30 ml/min over the last 3 months before study participation.

          3. The single use of either aspirin or Vitamin K Antagonists

          4. Provision of informed consent.

        Exclusion criteria:

          1. Unstable renal function and Creatinin Clearance &lt;15mL/min

          2. Patients treated with two or more platelet aggregation inhibitors

          3. Use of or indication for therapeutic  heparin

          4. Patients with prosthetic heart valves

          5. Haemorrhagic disorder or bleeding diathesis

          6. Platelet count &lt;100 109/L) at screening or during the last 30 days before screening.

          7. Participation in another drug trial in the last 30 days before screening.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.166.31001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>October 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
